Skip to content
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • X
  • en_US
  • ja
  • en_US
  • ja
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation

    Pharmacokinetics & distribution

    PK & Distribution
    Bioanalysis
    Vectors & gene therapy distribution
    Biomarker studies

    Behavioral tests

    Tinnitus detection
    GPIAS & PPI
    Hyperacusis

    Delivery capabilities

    Transtympanic
    Intracochlear
    Systemic

    Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    Screening / dose selection for ototoxicity or otoprotection

    In vitro on Otic cell line
    Ex vivo on Cochlear explants
    In vivo in Zebrafish

    Formulation

    Formulation for otic delivery

    Animal models

    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other disease & transgenic models
    Rodent & large species

    Our missions

    In vivo studies

    Auditory efficacy studies
    Auditory tolerance & safety studies
    Auditory phenotyping studies
    GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    Modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    Electrophysiology & electroacoustic

    ABR
    DPOAE
    Wave I to V analysis
    CAP & unicellular electrophysiology

    Ear assessment

    Otoscopy
    Tympanometry
    Gross middle ear assessment

    Pathology & histopathology

    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    Molecular biology & biochemistry

    Biochemistry
    Molecular biology

    OUR MISSIONS

    IN VITRO / EX VIVO / IN VIVO EFFICACY

    FORMULATION & DISTRIBUTION

    OTOTOXICITY

    CLINICAL AUDITORY BIOMARKER

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgeries

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Middle ear
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Auditory biomarkers in clinical trials

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Transtympanic
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Clinical biomarker studies

  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
Fichier 2
Read more about the article CILcare celebrates 5 years of success !

CILcare celebrates 5 years of success !

  • Post author:CILcare
  • Post published:18 July 2019
  • Post category:Events

CILcare was created in July 2014 by three managers from Sanofi, Celia Belline, Dr. Marie-Pierre Pasdelou and Dr. Sylvie Pucheu, who combined their skills to accelerate the development of innovate…

Continue ReadingCILcare celebrates 5 years of success !
Read more about the article CILcare will attend the 2nd Annual NPD Summit on July 24-25, 2019 in Boston

CILcare will attend the 2nd Annual NPD Summit on July 24-25, 2019 in Boston

  • Post author:CILcare
  • Post published:2 July 2019
  • Post category:Events

CILcare will attend the 2nd Annual Neuropsychiatric Drug Development Summit on July 24-25, 2019 in Boston. Meet Dr. Gaëlle NAERT, COO to know more about the link between hearing & neuropsychiatric disorders! Please…

Continue ReadingCILcare will attend the 2nd Annual NPD Summit on July 24-25, 2019 in Boston
Read more about the article CILcare at the AFSSI Connexions on July 2-3,2019 in Lyon, France

CILcare at the AFSSI Connexions on July 2-3,2019 in Lyon, France

  • Post author:CILcare
  • Post published:20 June 2019
  • Post category:Events

Meet CILcare at the Annual meeting of preclinical research AFSSI Connexions on July 2-3, 2019 in Lyon. Join Celia Belline, CEO, Dr. Sylvie Pucheu, CSO, and Dr. Wahid Awad, Director…

Continue ReadingCILcare at the AFSSI Connexions on July 2-3,2019 in Lyon, France
Read more about the article Meet CILcare on June 18th in Paris to discuss the latest advances in hearing field

Meet CILcare on June 18th in Paris to discuss the latest advances in hearing field

  • Post author:CILcare
  • Post published:3 June 2019
  • Post category:Events

Meet CILcare at Innovation meeting: European deep impact innovations. Perspectives 2030 on June 18th in Paris. Dr. Wahid AWAD, Director of Business Strategy and Alliances, will be pleased to discuss the latest advances…

Continue ReadingMeet CILcare on June 18th in Paris to discuss the latest advances in hearing field
Read more about the article Wahid AWAD, Ph.D, was promoted as Director of Business Strategy and Alliances

Wahid AWAD, Ph.D, was promoted as Director of Business Strategy and Alliances

  • Post author:CILcare
  • Post published:27 May 2019
  • Post category:Events

CILcare is pleased to announce the appointment of Dr. Wahid AWAD as the Director of Business Strategy and Alliances for CILcare. Dr. Awad was the Business Development Manager for CILcare…

Continue ReadingWahid AWAD, Ph.D, was promoted as Director of Business Strategy and Alliances
Read more about the article Meet CILcare at the STP 38th Annual Symposium on June 22-27,2019 in Ralegh, NC

Meet CILcare at the STP 38th Annual Symposium on June 22-27,2019 in Ralegh, NC

  • Post author:CILcare
  • Post published:23 May 2019
  • Post category:Events

Join CILcare and CBSET at the STP 38th Annual Symposium on June 22-27, 2019 in Raleigh, North Carolina. Meet our experts to learn about our cutting-edge GLP preclinical services for the evaluation…

Continue ReadingMeet CILcare at the STP 38th Annual Symposium on June 22-27,2019 in Ralegh, NC
Read more about the article CILcare at the BIO International Convention on June 3-6, 2019 in Philadelphia, PA

CILcare at the BIO International Convention on June 3-6, 2019 in Philadelphia, PA

  • Post author:CILcare
  • Post published:2 May 2019
  • Post category:Events

  CILcare will attend the BIO International Convention on June 3-6, 2019 in Philadelphia, PA. Meet Celia BELLINE, CEO, to learn more about our services in the field of hearing and discuss how we…

Continue ReadingCILcare at the BIO International Convention on June 3-6, 2019 in Philadelphia, PA
Read more about the article CILcare at the Meet’HIC by Medicen on April 15th in Paris

CILcare at the Meet’HIC by Medicen on April 15th in Paris

  • Post author:CILcare
  • Post published:15 April 2019
  • Post category:Events

Meet CILcare at the Meet'HIC by Medicen on April 15th in Paris. Dr. Wahid AWAD, Business Development Manager, will be pleased to discuss the latest advances in drug development in ear…

Continue ReadingCILcare at the Meet’HIC by Medicen on April 15th in Paris
Read more about the article CILcare will attend Tinnitus Research Initiative Conference on May 17-19, 2019 in Taipei

CILcare will attend Tinnitus Research Initiative Conference on May 17-19, 2019 in Taipei

  • Post author:CILcare
  • Post published:10 April 2019
  • Post category:Events

CILcare will be attending the 12th conference of Tinnitus Research Initiatives on May 17-19, 2019 in Taipei, Taiwan. Meet Sylvie COSNIER-PUCHEU, CSO, to learn more about our services in the field…

Continue ReadingCILcare will attend Tinnitus Research Initiative Conference on May 17-19, 2019 in Taipei
Read more about the article CILcare at the 12th Annual GDDIF Forum on May 14-15, 2019 in Amsterdam

CILcare at the 12th Annual GDDIF Forum on May 14-15, 2019 in Amsterdam

  • Post author:CILcare
  • Post published:9 April 2019
  • Post category:Events

CILcare will attend the 12th Annual Global Discovery to Development Innovation Forum on May 14-15, 2019 in Amsterdam. Meet Dr. Wahid AWAD, Business Development Manager to learn more about CILcare’s offer to…

Continue ReadingCILcare at the 12th Annual GDDIF Forum on May 14-15, 2019 in Amsterdam
  • Go to the previous page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 16
  • Go to the next page
Linkedin-in X
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
cilcare
MONTPELLIER • BOSTON • PARIS

info@cilcare.com

Intra-Community VAT: FR00803146125

cilcare | Mentions légales | Conception : Malice | Développement : Linov ©2026
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
About cilcare
Who we are
Our team
Scientific advisors
Hearing loss & Aging connection
External Innovation

Pharmacokinetics & distribution

PK & Distribution
Bioanalysis
Vectors & gene therapy distribution
Biomarker studies

Behavioral tests

Tinnitus detection
GPIAS & PPI
Hyperacusis

Delivery capabilities

Transtympanic
Intracochlear
Systemic

Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

Screening / dose selection for ototoxicity or otoprotection

In vitro on Otic cell line
Ex vivo on Cochlear explants
In vivo in Zebrafish

Formulation

Formulation for otic delivery

Animal models

Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other disease & transgenic models
Rodent & large species

Our missions

In vivo studies

Auditory efficacy studies
Auditory tolerance & safety studies
Auditory phenotyping studies
GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

Modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

Electrophysiology & electroacoustic

ABR
DPOAE
Wave I to V analysis
CAP & unicellular electrophysiology

Ear assessment

Otoscopy
Tympanometry
Gross middle ear assessment

Pathology & histopathology

Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

Molecular biology & biochemistry

Biochemistry
Molecular biology

OUR MISSIONS

IN VITRO / EX VIVO / IN VIVO EFFICACY

FORMULATION & DISTRIBUTION

OTOTOXICITY

CLINICAL AUDITORY BIOMARKER

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgeries

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Middle ear
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Auditory biomarkers in clinical trials

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Transtympanic
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

Therapeutics
Our missions
Our pipeline
Cochlear synaptopathy
Our clinical studies
Auditory Analytics
  • en_US
  • ja
  • en_US
  • ja
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok